The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Combretastatin     5-[(2S)-2-hydroxy-2-(3,4,5...

Synonyms: CHEBI:355514, ZINC01580527, LS-186802, LS-187471, AKOS015967221, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NSC 348103


High impact information on NSC 348103


Chemical compound and disease context of NSC 348103


Biological context of NSC 348103


Anatomical context of NSC 348103


Associations of NSC 348103 with other chemical compounds


Gene context of NSC 348103


Analytical, diagnostic and therapeutic context of NSC 348103


  1. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Dark, G.G., Hill, S.A., Prise, V.E., Tozer, G.M., Pettit, G.R., Chaplin, D.J. Cancer Res. (1997) [Pubmed]
  2. Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Dong, D., Ko, B., Baumeister, P., Swenson, S., Costa, F., Markland, F., Stiles, C., Patterson, J.B., Bates, S.E., Lee, A.S. Cancer Res. (2005) [Pubmed]
  3. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Malcontenti-Wilson, C., Muralidharan, V., Skinner, S., Christophi, C., Sherris, D., O'Brien, P.E. Clin. Cancer Res. (2001) [Pubmed]
  4. Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization. Cushman, M., Nagarathnam, D., Gopal, D., Chakraborti, A.K., Lin, C.M., Hamel, E. J. Med. Chem. (1991) [Pubmed]
  5. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Thoeny, H.C., De Keyzer, F., Vandecaveye, V., Chen, F., Sun, X., Bosmans, H., Hermans, R., Verbeken, E.K., Boesch, C., Marchal, G., Landuyt, W., Ni, Y. Radiology. (2005) [Pubmed]
  6. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Kanthou, C., Tozer, G.M. Blood (2002) [Pubmed]
  7. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Beauregard, D.A., Hill, S.A., Chaplin, D.J., Brindle, K.M. Cancer Res. (2001) [Pubmed]
  8. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Iyer, S., Chaplin, D.J., Rosenthal, D.S., Boulares, A.H., Li, L.Y., Smulson, M.E. Cancer Res. (1998) [Pubmed]
  9. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Li, L., Rojiani, A., Siemann, D.W. Int. J. Radiat. Oncol. Biol. Phys. (1998) [Pubmed]
  10. Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4. Zhao, S., Moore, J.V., Waller, M.L., McGown, A.T., Hadfield, J.A., Pettit, G.R., Hastings, D.L. European journal of nuclear medicine. (1999) [Pubmed]
  11. Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. Beauregard, D.A., Pedley, R.B., Hill, S.A., Brindle, K.M. NMR in biomedicine. (2002) [Pubmed]
  12. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Grosios, K., Loadman, P.M., Swaine, D.J., Pettit, G.R., Bibby, M.C. Anticancer Res. (2000) [Pubmed]
  13. Combretastatin A-1 phosphate potentiates the antitumor activity of carboplatin and paclitaxel in a severe combined immunodeficiency disease (SCID) mouse model of human ovarian carcinoma. Staflin, K., Järnum, S., Hua, J., Honeth, G., Kannisto, P., Lindvall, M. Int. J. Gynecol. Cancer (2006) [Pubmed]
  14. The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death. Kanthou, C., Greco, O., Stratford, A., Cook, I., Knight, R., Benzakour, O., Tozer, G. Am. J. Pathol. (2004) [Pubmed]
  15. The effects of colchicine analogues on the reaction of tubulin with iodo[14C]acetamide and N,N'-ethylenebis(iodoacetamide). Roach, M.C., Bane, S., Ludueña, R.F. J. Biol. Chem. (1985) [Pubmed]
  16. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a). Pettit, G.R., Singh, S.B., Boyd, M.R., Hamel, E., Pettit, R.K., Schmidt, J.M., Hogan, F. J. Med. Chem. (1995) [Pubmed]
  17. Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents. Cushman, M., Nagarathnam, D., Gopal, D., He, H.M., Lin, C.M., Hamel, E. J. Med. Chem. (1992) [Pubmed]
  18. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. Peifer, C., Stoiber, T., Unger, E., Totzke, F., Schächtele, C., Marmé, D., Brenk, R., Klebe, G., Schollmeyer, D., Dannhardt, G. J. Med. Chem. (2006) [Pubmed]
  19. The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Woods, J.A., Hadfield, J.A., Pettit, G.R., Fox, B.W., McGown, A.T. Br. J. Cancer (1995) [Pubmed]
  20. Combretastatins D-3 and D-4, new macrocyclic lactones from Getonia floribunda. Vongvanich, N., Kittakoop, P., Charoenchai, P., Intamas, S., Danwisetkanjana, K., Thebtaranonth, Y. Planta Med. (2005) [Pubmed]
  21. Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug. Pettit, G.R., Grealish, M.P., Herald, D.L., Boyd, M.R., Hamel, E., Pettit, R.K. J. Med. Chem. (2000) [Pubmed]
  22. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Thoeny, H.C., De Keyzer, F., Chen, F., Ni, Y., Landuyt, W., Verbeken, E.K., Bosmans, H., Marchal, G., Hermans, R. Radiology. (2005) [Pubmed]
  23. Novel combretastatin analogues endowed with antitumor activity. Simoni, D., Romagnoli, R., Baruchello, R., Rondanin, R., Rizzi, M., Pavani, M.G., Alloatti, D., Giannini, G., Marcellini, M., Riccioni, T., Castorina, M., Guglielmi, M.B., Bucci, F., Carminati, P., Pisano, C. J. Med. Chem. (2006) [Pubmed]
  24. Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions. Getahun, Z., Jurd, L., Chu, P.S., Lin, C.M., Hamel, E. J. Med. Chem. (1992) [Pubmed]
  25. Antineoplastic agents. 379. Synthesis of phenstatin phosphate. Pettit, G.R., Toki, B., Herald, D.L., Verdier-Pinard, P., Boyd, M.R., Hamel, E., Pettit, R.K. J. Med. Chem. (1998) [Pubmed]
  26. A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules. Sengupta, S., Kiziltepe, T., Sasisekharan, R. FASEB J. (2004) [Pubmed]
  27. Ocular neovascularization: a valuable model system. Campochiaro, P.A., Hackett, S.F. Oncogene (2003) [Pubmed]
  28. Combretastatin A-4 prodrug in the treatment of a murine model of retinoblastoma. Escalona-Benz, E., Jockovich, M.E., Murray, T.G., Hayden, B., Hernandez, E., Feuer, W., Windle, J.J. Invest. Ophthalmol. Vis. Sci. (2005) [Pubmed]
  29. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Pedley, R.B., Hill, S.A., Boxer, G.M., Flynn, A.A., Boden, R., Watson, R., Dearling, J., Chaplin, D.J., Begent, R.H. Cancer Res. (2001) [Pubmed]
  30. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41. Pettit, G.R., Rhodes, M.R., Herald, D.L., Hamel, E., Schmidt, J.M., Pettit, R.K. J. Med. Chem. (2005) [Pubmed]
  31. Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. Zhao, D., Jiang, L., Hahn, E.W., Mason, R.P. Int. J. Radiat. Oncol. Biol. Phys. (2005) [Pubmed]
WikiGenes - Universities